Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.
EFFICACY OF ABL001 - ALONE OR IN COMBINATION - ON CD34+ PROGENITORS ISOLATED FROM CML PATIENTS DISPLAYING HIGH OR LOW BCR-ABL TRANSCRIPTS AT DIAGNOSIS
Vol 32, Issue 4S1, 2018
Abstract
ABL001 (Asciminib) is a selective allosteric inhibitor of the BCR-ABL oncoprotein that binds to themyristoyl pocket of ABL favouring the formation of an inactive kinase conformation. We evaluated thesensitivity to ABL001 - alone or in combination with the tyrosine kinase inhibitors (TKIs) Imatinib (IM)and Nilotinib (NIL) - of CD34+ leukemic progenitors isolated from 30 patients displaying either high(n=15) or low (n=15) BCR-ABL/GUSIS levels at diagnosis.
References
Supporting Agencies
Copyright (c) 2018
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Medical Genetics, University of Torino Medical School, Italy
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy